Article

Quality of life in children and adults with constipation.

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Centennial Building, 4th floor, 1685 Highland Avenue, Madison, WI 53705, United States.
Best practice & research. Clinical gastroenterology (Impact Factor: 2.48). 02/2011; 25(1):19-27. DOI: 10.1016/j.bpg.2010.12.004
Source: PubMed

ABSTRACT This review summarises the literature on quality of life (QOL) assessments in both children and adults with functional constipation. Studies of adults with constipation include subjects from both tertiary care centres and population-based surveys whereas there are no population-based studies in children. The preponderance of evidence indicates that the adverse effects of chronic constipation on QOL in both children and adults are comparable to that seen in other chronic gastrointestinal and non-gastrointestinal disorders. There are no data on the effect of treatment of children with constipation with regard to QOL whereas several studies indicate that successful treatment of constipation in adults has a favourable effect on QOL. The emerging concept in the treatment of chronic constipation is to measure both objective measures such as frequency and ease of defecation and subjective parameters such as QOL.

0 Bookmarks
 · 
156 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To characterize functional bowel disorders in a population of pregnant women, evaluating effects on quality of life, management and follow-up.DesignProspective cohortSettingUniversity center, United States.PopulationWomen in the first trimester (n=104).Methods After enrollment evaluations, measures were repeated in the third trimester. Overall bowel function was assessed using the Rome III Questionnaire for Functional Bowel Disorders. Quality of life symptoms were assessed with the Irritable Bowel Syndrome Quality of Life Measure. Physician documentation of bowel symptoms and subsequent treatment in pregnancy were ascertained by retrospective chart review.Main Outcome MeasureQuality of life in first trimester.ResultsA majority (75%) of the women at the first trimester evaluation reported having one or more functional bowel disorders. The overall quality of life status was rated highly functional, with a total average score of 94.9. Of the 75 patients reporting functional bowel disorders, only 18 (24%) were identified in the medical record. Overall documentation of any bowel function was identified in the majority (64%) of cases. Most commonly no discussion of treatment was documented, while follow-up was recorded in only 27% of women with dysfunction.Conclusions Nearly three-quarters of women in the first trimester report symptoms consistent with functional bowel disorders. Overall quality of life measures are highly rated. There is a discrepancy between what women report regarding bowel dysfunction and what is documented by providers within the medical record.This article is protected by copyright. All rights reserved.
    Acta Obstetricia Et Gynecologica Scandinavica 05/2014; 93(9). DOI:10.1111/aogs.12434 · 1.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Constipation has a significant impact on the quality of life (QOL). Lifestyle modification is widely accepted and recommended by experts as first-line therapy.
    05/2014; 21(2):100-6. DOI:10.4103/2230-8229.134766
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dyschezia is a defecatory disorder that places a heavy burden on a patient's quality of life. Biofeedback is the recommended treatment in most cases. The objective of our study was to test whether a CO2-releasing suppository for patients with dyschezia could be effective in improving biofeedback training results. A randomized, double-blind, multicenter, placebo-controlled study was conducted in patients (18-75 years of age) with dyschezia defined according to the modified Rome III criteria. Patients were randomly assigned to either a CO2-releasing suppository or placebo suppository once per day for 21 days. This was a multicenter trial. A total of 122 patients were randomly assigned (62 intervention group and 60 placebo group). The primary end point was the change from day 0 to day 21 in intensity of symptoms on the basis of a self-assessed dyschezia using a visual analog scale (range, 0-100). Analyses were performed using intention-to-treat principles. A greater reduction from baseline to day 21 in symptom visual analog scale score was observed in the intervention group (-41.3 mm) than in the control group (-22.3 mm). Some secondary efficacy parameters improved more in the intervention group, including the percentage of patients who improved ≥50%, symptom intensity over 21 days, stool stains on underwear or pads, and need to practice manual maneuvers to facilitate defecation at day 21. At day 21, rectal sensitivity in the intervention group (31.4 mL) was lower than in the control group (39.1 mL). There was a lower number of patients recruited than planned by the protocol. The sponsor stopped the trial before the inclusion of 306 participants, with no intermediate analysis. In addition, the main analysis conducted on the full analysis set population could have led to a statistical bias. The results of this multicenter trial demonstrate the added benefits of a CO2-releasing suppository in patients with dyschezia who were treated by anorectal biofeedback training.
    Diseases of the Colon & Rectum 06/2014; 57(6):781-9. DOI:10.1097/DCR.0000000000000098 · 3.20 Impact Factor